SHENZHEN, China - TelAve -- At the start of the new year, Transtek Medical (300562.SZ) celebrates a double victory. On February 6, at the 2025 High-Quality Development Conference in Zhongshan Torch Development Zone, Transtek Medical was honored with two prestigious awards—"Top 10 Enterprises in R&D Investment Contribution" and the "Bai Qian Wan Project Contribution Award"—in recognition of its outstanding technological innovation and contributions to social and economic development.

Transtek Medical Recognized as a Top 10 Enterprise in R&D Investment Contribution

This award recognizes enterprises for their outstanding commitment to R&D investment. In addition to its headquarters in Zhongshan, Transtek Medical has established R&D centers in Shenzhen, Shanghai, and other locations. This continuous investment in R&D not only strengthens the company's core competitiveness but also provides strong support for regional economic innovation and development.

More on TelAve News

• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
• Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
• Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs

Transtek Medical Honored with the "Bai Qian Wan Project Contribution Award

This award was established as part of Guangdong Province's initiative to promote regional coordination, urban-rural integration, and industrial upgrading. It recognizes enterprises that have made outstanding contributions to local economic growth, industrial transformation, and rural revitalization. Transtek Medical actively fulfills its social responsibility, demonstrating strong corporate commitment and playing a key role in driving high-quality regional economic development.

Receiving both the "Top 10 Enterprises in R&D Investment Contribution" and the "Bai Qian Wan Project Contribution Award" at the 2025 High-Quality Development Conference in the Torch Development Zone is not only a strong recognition of Transtek Medical's outstanding past performance but also a testament to the high expectations for its future growth.

Founded in 2000, Transtek is committed to multiple health fields such as remote health and chronic disease management, providing customers with medical-grade "RPM devices" and "cloud services". Transtek also provides one-stop connectivity technology, device management, and fulfillment services for Remote Patient Monitoring (RPM) providers. Transtek has established a co-branded solution named TeleRPM since 2019, it stands for Quality & Value which is the best of Transtek. TeleRPM is an integrated solution which includes cellular blood pressure monitor, cellular weight scale, cellular blood glucose meter and all-round BLE package with AnyHub solution. Also, TeleRPM is open and scalable, and Transtek will leverage their expertise to help customers realize greater value, potential and outcomes.

More on TelAve News

• The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
• Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
• $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
• SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
• New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories